Raquel G Cao1, Nicolas M Suarez1, Gerlinde Obermoser2, Santiago M C Lopez1, Emilio Flano1, Sara E Mertz1, Randy A Albrecht3, Adolfo García-Sastre4, Asuncion Mejias5, Hui Xu2, Huanying Qin2, Derek Blankenship2, Karolina Palucka2, Virginia Pascual2, Octavio Ramilo5. 1. Center for Vaccines and Immunity, The Research Institute. 2. Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas. 3. Department of Microbiology Global Health and Emerging Pathogens Institute. 4. Department of Microbiology Global Health and Emerging Pathogens Institute Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Center for Vaccines and Immunity, The Research Institute Department of Pediatrics, Division of Infectious Diseases, Nationwide Children's Hospital The Ohio State University College of Medicine, Columbus, Ohio.
Abstract
BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children <5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.
BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children <5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.
Authors: Kathleen M Neuzil; Yuwei Zhu; Marie R Griffin; Kathryn M Edwards; Juliette M Thompson; Sharon J Tollefson; Peter F Wright Journal: J Infect Dis Date: 2001-12-17 Impact factor: 5.226
Authors: H S Izurieta; W W Thompson; P Kramarz; D K Shay; R L Davis; F DeStefano; S Black; H Shinefield; K Fukuda Journal: N Engl J Med Date: 2000-01-27 Impact factor: 91.245
Authors: Katherine A Poehling; Kathryn M Edwards; Geoffrey A Weinberg; Peter Szilagyi; Mary Allen Staat; Marika K Iwane; Carolyn B Bridges; Carlos G Grijalva; Yuwei Zhu; David I Bernstein; Guillermo Herrera; Dean Erdman; Caroline B Hall; Ranee Seither; Marie R Griffin Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Eva Negri; Carla Colombo; Laura Giordano; Nicola Groth; Giovanni Apolone; Carlo La Vecchia Journal: Vaccine Date: 2005-04-22 Impact factor: 3.641
Authors: Douglas M Fleming; Pietro Crovari; Ulrich Wahn; Timo Klemola; Yechiel Schlesinger; Alexangros Langussis; Knut Øymar; Maria Luz Garcia; Alain Krygier; Herculano Costa; Ulrich Heininger; Jean-Louis Pregaldien; Sheau-Mei Cheng; Jonathan Skinner; Ahmad Razmpour; Melanie Saville; William C Gruber; Bruce Forrest Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Gerlinde Obermoser; Scott Presnell; Kelly Domico; Hui Xu; Yuanyuan Wang; Esperanza Anguiano; Luann Thompson-Snipes; Rajaram Ranganathan; Brad Zeitner; Anna Bjork; David Anderson; Cate Speake; Emily Ruchaud; Jason Skinner; Laia Alsina; Mamta Sharma; Helene Dutartre; Alma Cepika; Elisabeth Israelsson; Phuong Nguyen; Quynh-Anh Nguyen; A Carson Harrod; Sandra M Zurawski; Virginia Pascual; Hideki Ueno; Gerald T Nepom; Charlie Quinn; Derek Blankenship; Karolina Palucka; Jacques Banchereau; Damien Chaussabel Journal: Immunity Date: 2013-04-18 Impact factor: 31.745
Authors: Min-Shi Lee; Kutubuddin Mahmood; Lopa Adhikary; Marilyn J August; Julie Cordova; Iksung Cho; George Kemble; Keith Reisinger; Robert E Walker; Paul M Mendelman Journal: Pediatr Infect Dis J Date: 2004-09 Impact factor: 2.129
Authors: Helder I Nakaya; Thomas Hagan; Sai S Duraisingham; Eva K Lee; Marcin Kwissa; Nadine Rouphael; Daniela Frasca; Merril Gersten; Aneesh K Mehta; Renaud Gaujoux; Gui-Mei Li; Shakti Gupta; Rafi Ahmed; Mark J Mulligan; Shai Shen-Orr; Bonnie B Blomberg; Shankar Subramaniam; Bali Pulendran Journal: Immunity Date: 2015-12-15 Impact factor: 31.745
Authors: Helder I Nakaya; Elizabeth Clutterbuck; Dmitri Kazmin; Lili Wang; Mario Cortese; Steven E Bosinger; Nirav B Patel; Daniel E Zak; Alan Aderem; Tao Dong; Giuseppe Del Giudice; Rino Rappuoli; Vincenzo Cerundolo; Andrew J Pollard; Bali Pulendran; Claire-Anne Siegrist Journal: Proc Natl Acad Sci U S A Date: 2016-01-11 Impact factor: 11.205
Authors: Kelly Stefano Cole; Judith M Martin; William T Horne; Chyongchiou J Lin; Mary Patricia Nowalk; John F Alcorn; Richard K Zimmerman Journal: Vaccine Date: 2017-11-11 Impact factor: 3.641
Authors: Jad Maamary; Taia T Wang; Gene S Tan; Peter Palese; Jeffrey V Ravetch Journal: Proc Natl Acad Sci U S A Date: 2017-09-05 Impact factor: 11.205
Authors: John F Alcorn; Raghunandan Avula; Anish B Chakka; William E Schwarzmann; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Marianna A Ortiz; William T Horne; Uma R Chandran; Jennifer P Nagg; Richard K Zimmerman; Kelly S Cole; Krissy K Moehling; Judith M Martin Journal: Hum Vaccin Immunother Date: 2020-04-16 Impact factor: 3.452